- Home
- APM vs XAIR Comparison
APM vs XAIR Comparison
Compare APM & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APM
- XAIR
- Stock Information
- Founded
- APM 2010
- XAIR 2011
- Country
- APM United Kingdom
- XAIR United States
- Employees
- APM N/A
- XAIR N/A
- Industry
- APM Biotechnology: Pharmaceutical Preparations
- XAIR Medical/Dental Instruments
- Sector
- APM Health Care
- XAIR Health Care
- Exchange
- APM Nasdaq
- XAIR Nasdaq
- Market Cap
- APM 18.9M
- XAIR 17.0M
- IPO Year
- APM 2018
- XAIR N/A
- Fundamental
- Price
- APM $1.39
- XAIR $1.76
- Analyst Decision
- APM
- XAIR Strong Buy
- Analyst Count
- APM 0
- XAIR 1
- Target Price
- APM N/A
- XAIR $11.00
- AVG Volume (30 Days)
- APM 113.6K
- XAIR 1.2M
- Earning Date
- APM 12-19-2025
- XAIR 11-10-2025
- Dividend Yield
- APM N/A
- XAIR N/A
- EPS Growth
- APM N/A
- XAIR N/A
- EPS
- APM N/A
- XAIR N/A
- Revenue
- APM N/A
- XAIR $4,782,000.00
- Revenue This Year
- APM N/A
- XAIR $261.11
- Revenue Next Year
- APM N/A
- XAIR $151.82
- P/E Ratio
- APM N/A
- XAIR N/A
- Revenue Growth
- APM N/A
- XAIR 168.20
- 52 Week Low
- APM $0.46
- XAIR $1.64
- 52 Week High
- APM $7.49
- XAIR $13.52
- Technical
- Relative Strength Index (RSI)
- APM 35.35
- XAIR 33.05
- Support Level
- APM $1.43
- XAIR $1.65
- Resistance Level
- APM $1.43
- XAIR $2.07
- Average True Range (ATR)
- APM 0.08
- XAIR 0.18
- MACD
- APM -0.01
- XAIR -0.04
- Stochastic Oscillator
- APM 9.27
- XAIR 14.46
About APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. The company operates in one segment: research and development. The projects are ALS-4, SACT-1, and RPIDD. It is also engaged in providing healthcare services.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.